Ā | Mild coagulopathy (nā=ā37) | Severe coagulopathy (nā=ā32) | P value |
---|---|---|---|
Male, n (%) | 25 (67.6) | 23 (71.9) | 0.796 |
Age (years) | 69 [38ā94] | 72.5 [33ā91] | 0.110 |
Shock, n (%) | 14 (42.4) | 13 (40.6) | 1.000 |
AKI, n (%) | 15 (42.9) | 18 (56.3) | 0.332 |
APACHE II score | 26.6āĀ±ā8.1 | 29.8āĀ±ā10.8 | 0.229 |
SOFA score | 6.2āĀ±ā3.5 | 7.5āĀ±ā2.5 | 0.114 |
ISTH overt DIC score | 3.4āĀ±ā0.7 | 5.3āĀ±ā0.6 | <ā 0.001 |
Mechanical ventilation, n (%) | 31 (88.6) | 30 (93.8) | 0.675 |
Renal replacement therapy, n (%) | 25 (71.4) | 22 (68.8) | 1.000 |
Vasopressor use, n (%) | 24 (68.6) | 24 (75.0) | 0.598 |
Lactate (mmol/L) | 32.0āĀ±ā22.8 | 38.3āĀ±ā21.5 | 0.289 |
Time for normalize lactate level (h) | 94.8āĀ±ā142.6 | 88.3āĀ±ā87.0 | 0.854 |
Cancer, n (%) | 6 (16.7) | 5 (15.6) | 1.000 |
rhTM dose (mg/kg) | 0.041āĀ±ā0.018 | 0.048āĀ±ā0.023 | 0.218 |
Duration of rhTM administration (days) | 5.4āĀ±ā1.8 | 6.3āĀ±ā3.5 | 0.181 |
Coagulation tests | |||
āProthrombin time ratio | 1.34āĀ±ā0.28 | 1.42āĀ±ā0.26 | 0.212 |
āAntithrombin III activity (%) | 57.7āĀ±ā20.6 | 54.5āĀ±ā21.8 | 0.581 |
āD-dimer (103Ā ng/ml) | 14.0āĀ±ā15.4 | 40.0āĀ±ā65.0 | <ā 0.001 |
āPlatelet count (103/Ī¼l) | 10.0āĀ±ā10.1 | 5.3āĀ±ā3.2 | 0.004 |
āFibrinogen (mg/dl) | 420.3āĀ±ā216.7 | 410.0āĀ±ā117.7 | 0.813 |